

November 18, 2022

Dr. Mélanie Bourassa Forcier
Interim Chair
Patented Medicine Prices Review Board (PMPRB)
Box L40, Standard Life Centre
1400-333 Laurier Avenue West
Ottawa, ON K1P 1C1

Via email: melanie.bourassa.forcier@usherbrooke.ca

Dear Dr. Bourassa Forcier:

On behalf of Innovative Medicines Canada (IMC), I am writing to you with respect to the revised draft Guidelines (Guidelines) released by the Patented Medicine Prices Review Board (PMPRB) for consultation on October 6, 2022. Specifically, IMC's leadership requests a meeting with you and with the other members of the PMPRB's Board of Directors to discuss our membership's significant concerns with the Guidelines.

Given that the PMPRB's consultation period with respect to the Guidelines ends on December 5, 2022, and that the Board intends to have a final set of Guidelines in place by the end of 2022, we would request that the meeting take place at your earliest convenience.

Thank you for your consideration of this request. Should you have any questions or if I can be of any further assistance, please do not hesitate to contact me.

Sincerely,



Pamela C. Fralick
President

cc: Sherri Wilson, Director, Board Secretariat, PMPRB, sherri.wilson@pmprb-cepmb.gc.ca